Tumor cells adaptation to severe oxygen deprivation (hypoxia) plays a major role in tumor progression. The transcription factor HIF-1 (hypoxia-inducible factor 1), whose a-subunit is stabilized under hypoxic conditions is a key component of this process. Recent studies showed that two members of the phosphoinositide 3-kinase-related kinases (PIKKs) family, ATM (ataxia telangiectasia mutated) and DNA-PK (DNA-dependent protein kinase), regulate the hypoxic-dependent accumulation of HIF-1. These proteins initiate cellular stress responses when DNA damage occurs. In addition, it has been demonstrated that extreme hypoxia induces a replicative stress resulting in regions of single-stranded DNA at stalled replication forks and the activation of ATR (ataxia telangiectasia and Rad3 related protein), another member of the PIKKs family. Here, we show that even less severe hypoxia (0.1% O 2 ) also induces activation of ATR through replicative stress. Importantly, in using either transiently silenced ATR cells, cells expressing an inactive form of ATR or cells exposed to an ATR inhibitor (CGK733), we demonstrate that hypoxic ATR activation positively regulates the key transcription factor HIF-1 independently of the checkpoint kinase Chk1. We show that ATR kinase activity regulates HIF-1a at the translational level and we find that the elements necessary for the regulation of HIF-1a translation are located within the coding region of HIF-1a mRNA. Finally, by using three independent cellular models, we clearly show that the loss of ATR expression and/or kinase activity results in the decrease of HIF-1 DNA binding under hypoxia and consequently affects protein expression levels of two HIF-1 target genes, GLUT-1 and CAIX. Taken together, our data show a new function for ATR in cellular adaptation to hypoxia through regulation of HIF-1a translation. Our work offers new prospect for cancer therapy using ATR inhibitors with the potential to decrease cellular adaptation in hypoxic tumors.
INTRODUCTION
Hypoxic areas are frequently found in human solid tumors as a result of morphologically and functionally inappropriate vascularization, irregular blood flow, anemia and high oxygen consumption of rapidly proliferating cells. 1, 2 A large body of clinical evidence suggests that intra-tumoral hypoxia correlates with the elevated aggressive behavior of cancer cells and their resistance to therapy, leading to poor patient prognoses. 3 Tumor cells must adapt to hypoxic stress through alterations of cellular metabolism and stimulation of neovascularization. A key regulator of the cellular response to oxygen deprivation is the transcription factor hypoxia-inducible factor 1 (HIF-1) whose accumulation results in the induction of a plethora of target genes that collectively confer cellular adaptation to hypoxia.
1 HIF-1 is comprised of a labile oxygen-regulated a-subunit mainly targeted for normoxiadependent degradation by the proteasomal system, whereas its b-subunit is constitutively expressed in most cells. 1, 4, 5 Therefore, HIF-1 activity is dependent upon the limiting expression of a-subunit. Under hypoxia, HIF-1a is stabilized, enters the nucleus and heterodimerizes with HIF-1b. The heterodimer HIF-1 binds hypoxia-responsive elements to transactivate a variety of hypoxiaresponsive genes, therefore contributing to the adaptative response to hypoxic conditions. 1 HIF-1 is overexpressed in many human cancers and correlates with poor prognosis outcome. 6 In most of these cases, over-expression is due to the stabilization of the HIF-1a protein by hypoxia. However, there is an increasing body of evidence demonstrating that a number of non-hypoxic stimuli such as genetic alterations that activate oncogenes and inactivate tumor suppressor genes or growth factors signaling are also highly capable of turning on this transcription factor. 5 Accordingly, HIF-1 represents an attractive, yet challenging, target for the development of pharmacological inhibitors. 5, 7 We and others have recently demonstrated that the hypoxic accumulation of HIF-1 is regulated by the DNA-dependent protein kinase (DNA-PK) and ataxia telangiectasia mutated (ATM), two members of the phosphoinositide 3-kinase-related kinases (PIKKs) family, 8, 9 that in eukaryotes initiate cellular stress responses when genome integrity, mRNA translation, or nutrient availability is compromised. 10 We have shown that DNA-PK, a key player of DNA double-strand breaks (DSBs) repair by the non-homologous end-joining pathway, is activated by mild hypoxia conditions (o1% O 2 ). 8 Activated DNA-PK positively regulates nuclear HIF-1a accumulation and subsequent levels of expression of HIF-1 target genes. 8 More severe hypoxia (o0.1% O 2 ) also activates ATM, 11, 12 an essential building block of the DNA DSBs signaling pathway. 13 It has been recently shown that ATM also increases HIF-1a expression and HIF-1-dependent transcription under hypoxic conditions. 9 Interestingly, the mechanism of hypoxia-induced activation of both DNA-PK and ATM is distinct from that of the DNA DSBs and is 1 CNRS, IPBS (Institut de Pharmacologie et de Biologie Structurale), Toulouse, France and likely to involve modification of higher-order chromatin structure and chromatin-remodeling complexes. 8, 9, 12 ATR (for ataxia telangiectasia and Rad3 related kinase), another member of the PIKKs family, is also involved in DNA damage signaling.
14 ATR controls a pathway that is mainly activated by agents that interfere with the functions of replication forks such as hydroxyurea or ultraviolet light 15 but also responds to DSBs in an ATM-dependent manner. [16] [17] [18] [19] Hypoxia itself is also known to induce a replication-associated damage response. For example, severe hypoxia induces S-phase arrest resulting in regions of single-stranded DNA (ssDNA) at stalled replication forks and the activation of ATR. 20, 21 Loss of ATR results in a further loss of viability in S-phase cells under hypoxic conditions. 22 In accordance to the emerging role of PIKKs in hypoxic adaptation, our experiments are designed to determine a potential role of ATR in the regulation of HIF-1 expression and function. Here we demonstrate that, under severe hypoxic conditions (0.1% O 2 ), ATR is activated at early time points and that this cellular stress response favors hypoxia adaptation by regulating HIF-1a protein synthesis. In addition to ATM and DNA-PK, our data emphasize the new and important role of ATR in the regulation of HIF-1 hypoxic accumulation.
RESULTS
ATR is activated through replicative stress in hypoxic cells and regulates HIF-1 expression and function To investigate if ATR could regulate the expression of HIF-1a upon hypoxia, we first evaluated in U2OS cells the effect of ATR knockdown using two independent small interfering RNAs (siRNAs), achieving a knockdown of around 80% of ATR expression ( Figure 1a ). Transfected cells were placed in a 21% (normoxia) or 0.1% (hypoxia) oxygen atmosphere for 6 h. As a control of ATR activation, the level of Chk1 (checkpoint kinase 1) phosphorylation on serine 345 was monitored, as this site is a well-known ATR target. 23 As previously described for extreme hypoxia (o0.02% O 2 ), 21 we detected a specific increase of the phosphorylated Chk1 in cells exposed to 0.1% O 2 , confirming ATR activation in our experimental conditions. In hypoxic cells, Chk1 phosphorylation was completely abrogated by ATR knockdown compared with control RNAi. Interestingly, ATR silencing almost completely abrogated HIF-1a protein accumulation upon hypoxia (490% decrease for si1 and si2). In U2OS cells, the b-subunit of HIF-1 is induced by hypoxia. This result was rather unexpected since HIF-1b is generally considered as a constitutively express protein that is not regulated by oxygen levels in most cells. 1, 4, 5 The molecular mechanism underlying the induction of HIF-1b in this specific model remains at the present time uncharacterized. Under hypoxic conditions, ATR knockdown was also paralleled by a significantly lower HIF-1b content (around 80% for si1 and 90% for si2). Taken together, these results emphasize that ATR is activated by severe hypoxic conditions and participates to HIF-1 accumulation under hypoxia.
We then investigate if the kinase activity of ATR was required for the observed effect on HIF-1. Since no specific pharmacological ATR inhibitor was available, we used CGK733, a small molecule that inhibits both ATM and ATR kinase activities and blocks their checkpoint signaling pathways. 24 In parallel, a specific inhibitor of --+  --+  -+  --+  ---+  --+  -+  --+  - ATR regulates HIF-1 expression F Fallone et al ATM, KU55933 was used as a control. 25 Exposure to CGK733, but not KU55933, was able to inhibit Chk1 phosphorylation upon hypoxic conditions confirming the absence of effect of KU55933 on ATR activity (Figure 1b) . A large decrease of HIF-1a and HIF-1b hypoxic accumulation was observed in cells treated with CGK733, whereas only a slight effect was observed with KU55933 treatment. Similar results were obtained in HeLa cells (Figure 1c) . We then used ATR-inducible cell lines expressing either a catalytically inactive (kinase-dead, KD) mutant or a wildtype (WT) form of the protein. 26 From 4 h of hypoxia, the accumulation of HIF-1a was dramatically reduced in ATR KD cells compared with WT cells, confirming the involvement of the kinase activity of ATR in the observed effect (Figure 1d ). To investigate if our results could be mediated by the ATR-activated Chk1 kinase, Chk1 expression was knocked-down using RNAi. In conditions where Chk1 was efficiently silenced (490% decrease in Chk1 expression) (Figure 1e ), the hypoxic levels of HIF-1a and b proteins were similar to control and the down-regulation of both HIF-1 subunits in the presence of CGK733 was still observed in the Chk1-depleted cells. Therefore, our compelling results highlight that activated ATR is able to regulate hypoxic HIF-1 accumulation in a Chk1-independent manner.
We next performed in HeLa cells time-course experiments to address the kinetics of CGK733-mediated inhibition of HIF-1a protein accumulation. CGK733 decreased the hypoxic-dependent accumulation of HIF-1a protein by about 50% after 60 min of treatment as compared with untreated controls, with almost complete abrogation of its expression observed after 2 h (Figure 2a) . The HIF-1b protein levels decreased only after 2 h of treatment (expression levels reduced to about 25% of the untreated control) (Figure 2a ) with no further additional effect for longer incubation times (data not shown). We then examined the dose-dependent effect of CGK733 on HIF-1a protein accumulation. CGK733 decreased hypoxic accumulation of HIFa protein in a dose-dependent manner with an IC 50 of 3.1 mM (Figure 2b) . Again, the effect on HIF-1b was less pronounced with an IC 50 of 18 mM. Therefore, these results demonstrate that the ATR-dependent inhibition of HIF-1 is an early event occurring during the first hours of incubation in hypoxic conditions with a more rapid and pronounced effect on the a-subunit of the complex.
We then investigated the signal that triggered ATR activation in these hypoxic conditions. Using a nuclear fractionation technique, we have previously demonstrated that hypoxia triggered loading of DNA-PK in a chromatin detergent-resistant fraction that also contained the HIF-1 subunits. 8 Similar ATR relocalization in detergent-resistant fractions has been shown to occur after exposure to drugs such as hydroxyurea or aphidicolin that induce rapid replication arrest. 17 In accordance with our previous work, 8 we observed here that activated DNA-PK was recruited to the extraction-resistant fraction FIV in hypoxic cells as compared with cells grown in normoxia (Figure 3a) . It is noteworthy that, in our conditions, the phosphorylated form of the histone variant H2AX (g-H2AX) and the chromatin-associated protein HP1a were only present in the fraction FIV assessing the quality of subfractionation, with a significant increase of g-H2AX expression in hypoxic cells as previously described. 8 In hypoxic cells, ATR was redistributed onto the latest fractions (FIII and FIV) along with its partner ATRIP (ATR-interacting protein), reflecting its chromatin loading. 17 Interestingly, this recruitment in hypoxic cells occurs along with the recruitment of the ssDNA-binding protein RPA (replication protein A). These results are in accordance with several observations that have highlighted the importance of RPAcoated ssDNA in ATR activation. 27 Finally, the HIF-1 subunits were mainly associated with the extraction-resistant fraction FIV as previously shown. 8 These results demonstrate that our experimental conditions lead to an early replication stress that triggers activation of ATR. Analysis of the cell-cycle distribution showed that cells exposure to low oxygen concentration (0.1%) induces at 12 h a cell-cycle arrest marked by a large decrease in G2/M (from 13.5 to 5.6%) and an accumulation of cells in G1-phase (from 55.2 to 69.3%) as compared with cells grown in normoxia (Supplementary Figure 1) . CGK733, but by neither KU55933 nor NU7026 (a DNA-PK-specific inhibitor), 28, 29 significantly affected this cell-cycle arrest (increase in G2/M from 5.6 to 15.3% and decrease in G1/S from 69.3 to 55% in CGK733-treated cells as compared with untreated cells) confirming the existence of a replicative stress in these cells whose signaling is regulated by ATR. To reinforce the hypothesis that replication stress was involved in the ATR-mediated regulation of HIF-1, we used aphidicolin, a known inhibitor of DNA replication. 30 Cells were treated with CGK733 in the presence or not of aphidicolin and then cultured under hypoxic conditions. Aphidicolin treatment in combination with CGK733 enhances the decrease of HIF-1 expression observed in the presence of CGK733 alone ( Figure 3b ). Taken together, using different approaches we demonstrated that ATR is activated by a replicative stress under our hypoxic conditions, and that this activation triggers the control of HIF-1 accumulation. (Aph) and CGK733. Protein levels were analyzed by western blots using the indicated antibodies. The levels of HIF-1a and HIF-1b expression in treated samples compared with controls (arbitrarily set at 1) are indicated, after normalization with a-tubulin expression levels. For HIF-1a, the hypoxic untreated cells are used as a control whereas untreated normoxic cells are used as a control of HIF-1b expression.
ATR regulates the translation of HIF-1a under hypoxic conditions Our first set of results demonstrates that ATR activity is involved in the regulation of both HIF-1 subunits with a more pronounced effect on the labile HIF-1a subunit. As HIF-1a protein is degraded mainly through the ubiquitin/proteasome pathway, experiments were performed to evaluate if activated ATR has the ability to interfere with the mechanism(s) responsible for HIF-1a protein stabilization and degradation. In hypoxia, CGK733, as well as KU55933, inhibited the accumulation of HIF-1a protein despite the presence of the proteasome inhibitor MG132, whereas in similar conditions, the difference in HIF-1a accumulation between NU7026-treated cells versus untreated cells were no longer observed in accordance with our recent published data 8 ( Figure 4a, upper panel) . Note that MG132 treatment leads to a clear increase in b-catenin expression as expected. 26 Similar results were obtained with another proteasome inhibitor, lactacystin (data not shown). In addition, we assessed that siRNAs against ATR were still efficient to inhibit HIF-1a expression in the presence of MG132 (Figure 4a , lower panel). To confirm that ATR does not regulate HIF-1a through its degradation, DFX (desferrioxamine)-treated cells were exposed to the protein synthesis inhibitor, cycloheximide (CHX) to block further HIF-1a mRNA translation. The kinetics of HIF-1a decay in CGK733-treated and untreated cells was compared by immunoblotting and no differences were observed between these two conditions ( Figure 4b, upper panel) . Similarly, no differences were observed when the HIF-1a degradation was compared between ATR WT versus KD cells (Figure 4b, lower panel) . Taken together, this set of experiments excludes a role for ATR in the control of HIF-1a stability and supports its involvement in the control of HIF-1a biosynthesis.
Under hypoxia no differences in HIF-1a and HIF-1b mRNA levels were observed between ATR-deficient and -proficient cells as seen by using CGK733-treated cells or the ATR WT/KD cellular model (see Supplementary Figure 2 ). These results strongly suggest that ATR-mediated regulation of HIF-1 expression occurs at the translational level. Consistently, inhibition of ATR expression (using ATR siRNA) and activity (CGK733-treated cells and ATR KD cells) decreased de novo synthesis of HIF-1a, as supported by a twofold reduction of 35 S-methionine/cysteine incorporation into HIF-1a in ATR-deficient cells as compared with controls ( Figure 4c ). Note that in these conditions, ATR depletion or inhibition was without effect on the translation of b-catenin used as a control (Figure 4c ). Taken together, these compelling results demonstrate ATR regulates HIF-1 expressionthat inhibition of ATR reduces HIF-1 translation without affecting its mRNA expression or proteasome degradation. Translation can be regulated at multiple levels and several mechanisms have already been described for HIF-1a.
31-33 The PI3K-AKT-mTOR (mammalian target of rapamycin) pathway has been implicated in the regulation of HIF-1a protein at a translational level. 34, 35 mTOR is able to stimulate translation by alleviating the inhibitory effect of 4E-BP1 on translation initiation, 36 through the phosphorylation on threonine 37/46. To test the involvement of mTOR, 4E-BP1 T37/46 phosphorylation was monitored in HeLa cells under normoxic or hypoxic conditions using the PI3K inhibitor LY294002 as a control (Supplementary Figure 3) . While LY294002 inhibited hypoxiainduced HIF-1a protein accumulation as described 37 and the phosphorylation of 4E-BP1 on threonine 37/46, CGK733 inhibited HIF-1a accumulation but did not affect the phosphorylation of 4E-BP1, in both normoxia and hypoxia (Supplementary Figure 3) . These results demonstrate that the effect of CGK733 on HIF-1a accumulation is independent of the PI3K-AKT-mTOR pathway.
A way to determine what is the mechanism regulating HIF-1a translation is to define the region of HIF-1a mRNA that confers regulation by ATR. In fact, HIF-1a 5 0 -untranslated region (UTR) contains an internal ribosome entry site (IRES) that has been reported to mediate its translation during hypoxia 38 and 3 0 UTR are known to be targeted by miRNA. 39 To define the HIF-1a mRNA regions conferring regulation by ATR, HIF-1a was transiently expressed under the control of a strong constitutive CMV (cytomegalovirus) promoter either as full-length cDNA, containing 5 0 UTR and 3 0 UTR (5 0 ORF3 0 ), or just its open reading frame (ORF). All the constructions used are summarized in Figure 5a . Results show that exposure of cells to the ATR inhibitor CGK733 is able to efficiently down-regulate the CMV-driven expression of both HIF-1a full-length cDNA containing HIF-1a ORF (ORF) as well as 5 0 and 3 0 UTR (5 0 ORF3 0 ) (Figure 5b) . A similar regulation is observed when HIF-1a ORF is fused to the GFP coding sequence (ORF-GFP). Furthermore, CGK733 exposure was unable to down-regulate the 5 0 UTR or the 3 0 UTR fused to GFP (5 0 UTR-GFP, 3 0 UTR-GFP) (Figure 5c ). Finally, siRNA-mediated depletion of ATR was showing a similar decrease of the expression of HIF-1a ORF-GFP as compared with control siRNA (Figure 5d ). Taken together, our results show that ATR expression and kinase activity regulates HIF-1a translation during hypoxia through a region contained in HIF-1a ORF.
ATR kinase activity is necessary for cellular adaptation to hypoxia We then checked if ATR expression and activity are involved in the cell adaptive response to hypoxia by using three different cell models: ATR WT versus KD cells, U2OS treated or not with CGK733 and U2OS transfected with siRNAs targeted against ATR versus control siRNA. Our previous results (see Figure 2a) show that, in hypoxic cells, HIF-1 is mainly present in the detergent-resistant fraction (FIV) of the extracts that is thought to be the chromatinassociated and therefore active form of the complex. We first demonstrated that exposure to CGK733 dramatically reduces the expression of both HIF-1 subunits in the detergent-resistant fraction FIV (Figure 6a ). This decrease is observed, but to a lesser extent after treatment with KU55933. The hypoxic expression of HIF-1 in the FIV fraction of ATR KD extracts was largely reduced as compared with similar extracts obtained from WT cells (Figure 6b ) and similar results were obtained in ATR-silenced cells as compared with control ( Figure 6c ). We then evaluated the expression of two HIF-1 target genes involved in the metabolic adaptation to hypoxia, the glucose transporter GLUT-1 and the carbonic anhydrase IX (CAIX), a membrane spanning protein involved in the enzymatic regulation of tumor acid-base balance. 40, 41 By using U2OS treated or not with CGK733, ATR WT versus KD cells and U2OS transfected with targeted siRNAs against ATR versus control siRNA, we clearly show that the mRNA expression levels of GLUT-1 and CAIX were significantly higher in hypoxic ATR-proficient than -deficient cells (Figures 6d-f) . Note that, in these conditions, we also observed a decrease in GLUT-1 and CAIX expression in KU55933-treated cells (Figure 6d) .
These results were also confirmed at proteins levels. In WT cells, the expression of both GLUT-1 and CAIX was induced after 12 h of hypoxia and maintained thereafter (Figure 6g ). This induction was Similarly, the expression of these two proteins was reduced in cells treated for 24 h with CGK733 (Figure 6h ). Finally, ATR silencing using siRNAs almost completely abrogated GLUT-1 and CAIX accumulation in cells exposed for hypoxia during 12 h (Figure 6i ).
Finally, we observed a specific decrease in cell survival upon hypoxia in cells where the ATR expression and activity was inhibited (see Supplementary Figure 4) . Therefore, our compelling results highlight that ATR kinase activity is able to regulate HIF-1 accumulation and to contribute to an efficient hypoxic adaptation. 
DISCUSSION
The DDR (DNA damage response) induced during hypoxic stress has recently emerged as an important signaling pathway that allows cells to withstand modifications in environmental conditions. Recent studies showed that two members of the PIKKs family involved in DNA DSBs signaling and repair, ATM and DNA-PK regulate the hypoxic-dependent accumulation and degradation of HIF-1a. 2, 8, 9, 42, 43 The histone variant H2AX, a target of PIKKs that participates in DDR and repair, has also been identified as a crucial actor for hypoxia-driven neovascularization. 44 We show here that another member of the PIKKs superfamily, ATR, activated by severe hypoxia (0.1% O 2 ) through replicative stress, regulates the expression of both HIF-1 subunits, therefore contributing to cell adaptation to hypoxia. Interestingly, a functional ATR was required to observe this effect that involves, for the a-subunit of HIF-1, the regulation of its translation. The involvement of ATR kinase activity in this novel regulation pathway raises the possibility of using ATR inhibitors to eradicate hypoxic cells during cancer therapy.
It has been previously demonstrated that the replicative stress induced by extreme hypoxia (from 0.02 to o0.1% O 2 ) leads to the activation of ATR. 20, 22, 45 In addition to these reports, our current data show that ATR is activated under less severe hypoxic conditions (0.1% O 2 ) in a similar replication-dependent manner. Indeed, we have shown that exposure of cells to these hypoxic conditions induces a cell-cycle arrest as well the phosphorylation of Chk1, both events being dependent of activated ATR (see Supplementary Figure 1 and Figures 1a-c) . In hypoxic cells, relocalization of ATR, concomitantly with its partner ATRIP and the ssDNA-binding protein RPA, into chromatin-associated fractions outlined the existence of a replicative stress (Figure 3a) .
What are the cellular end points of ATR activation in hypoxic cells? Recent study demonstrates that hypoxic activation of ATR is responsible for the activation of the DNA replication initiation checkpoint 45 but the downstream events, independently of cellcycle arrest, remain in fact poorly characterized. We report here for the first time that expression and activity of ATR positively regulates HIF-1 expression under hypoxia in different cellular models suggesting a canonical pathway (see Figure 1) . These results were obtained in cells where ATR expression was abrogated as well as in cells expressing an inactive form of the protein. Finally, the use of an ATR inhibitor, CGK733 reproduces this effect. We also showed that the inactivation of ATR through expression of a KD form of the protein or pharmacological inhibition of its kinase activity, as well as inhibition of its expression by siRNA, negatively regulates HIF-1 trans-activating function through expression of two of its target gene GLUT-1 and CAIX (see Figures 6d-i) . Inhibition of ATR expression and activity also inhibited cell survival upon hypoxic conditions (Supplementary Figure 4) . Interestingly, another work has recently uncovered a potential link between replicative stress and cellular adaptation to hypoxia in the specific model of endothelial cells. 44 In fact, this study demonstrated that hypoxia induces replicationassociated generation of g-H2AX (the phosphorylated form of the histone variant H2AX) in endothelial cells in vitro and in mice. 44 Moreover, endothelial-specific H2AX deletion resulted in reduced hypoxia-driven retina and tumor neovascularization. Therefore, while not directly demonstrating the role of HIF-1 in this process, this work underlined that activation of a replicative stress response (through H2AX phosphorylation) is crucial for hypoxiadriven neovascularization. According to these results, including ours, we propose a model whereas severe hypoxia induces a replicative stress, initiating ATR activation and contributing to an adaptive response, through regulation of HIF-1 expression, to counterbalance oxygen deprivation. The role of ATR in maintaining a suitable level of HIF-1 in cells exposed to severe hypoxia explains why inhibiting its function or expression contributes to down-regulate HIF-1 expression. Accordingly, in cells exhibiting a high level of replicative stress (such as the hypoxic cells exposed to aphidicolin, a known inhibitor of DNA replication, Figure 3b ), the inhibition of ATR is a very efficient approach to inhibit HIF-1 expression. These results are in apparent contradiction with the study of Rapisarda and Melillo 46 showing that HIF-1a accumulation is not further inhibited when ATRdeficient cells are exposed to UVC, a DNA-damaging agent known to interfere with DNA replication. However, in this study the authors showed that exposure to UVC alone inhibit HIF-1a translation. 46 This inhibition is dissociated from the induction of DNA lesions, suggesting the involvement of a specific pathway independent of an intact sensing of DNA damage, in contrast to our study. 46 Finally, it is interesting to note that no further increase in HIF-1 expression level is observed when hypoxic ATR-proficient cells are exposed to aphidicolin (see Figure 3b ). HIF-1 protein level is tightly regulated 1, 4, 5, 47 and one might speculate that some compensatory mechanisms exist limiting the level of expression of HIF-1 to a given range. This hypothesis could explain why increasing the replicative stress above a certain threshold do not contribute to further increase the accumulation of the protein.
Although we show that activation of ATR affects the hypoxic expression of both HIF-1 subunits, the expression of the labile asubunit appears to be more sensitive to ATR inhibition as emphasized in the time and dose experiments with CGK733 ( Figure 2) . In contrast to most of the known regulation mechanisms of HIF-1a hypoxic accumulation, which occur at the level of HIF-1a protein degradation, we found that the ATRdependent regulation of HIF-1a accumulation during hypoxia occurs at the stage of HIF-1a translation. Up-regulation of translation through the PI3K-AKT-mTOR pathway is an important mechanism of HIF-1a-protein accumulation induced by growth factors under aerobic conditions. 34, 48 However, the fact that ATR inhibition was without effect on the amount of phosphorylated 4E-BP1, a downstream target of mTOR does not favor this hypothesis (Figure 5a ). Other studies have reported a negative regulation of HIF-1a translation. The translation efficiency of individual genes is thought to be regulated largely by the 5 0 -and 3 0 -untranslated parts of the mRNA. It has been reported that HIF-1a protein translation can persist during hypoxia, owing to an IRES in the 5 0 UTR of its mRNA 38 whose activity is regulated by IRES trans-acting factors. 32, 49 We demonstrated here that inhibition of ATR expression and activity was able to efficiently down-regulate the expression of transfected HIF-1a full-length cDNA but also a minimum cDNA just containing the ORF ( Figure 5 ). In contrast, this inhibition fails to negatively regulate the expression of constructs containing either the 5 0 UTR or the 3 0 UTR regions of HIF-1a fused to GFP, ruling out the involvement of the IRES present in the 5 0 UTR of HIF-1 mRNA in the observed effect. MicroRNAs (miRs) have been postulated to influence HIF-1a expression in response to hypoxia 50 or in a way independent of hypoxia. 51 miRs are short non-coding RNAs that bind their target mRNAs, usually at sites within the 3 0 UTR, to destabilize mRNA and/or inhibit its translation. Interestingly, effective miR-binding sites have also been recently identified in ORFs and it is suggested they function with a similar mechanism to miRNA targeting 3 0 UTR sites. 52 Therefore, this mechanism remains an attractive hypothesis to explain the observed effect on HIF-1a translation, which warrants further investigation. In addition to the a-subunit of HIF-1, our work shows that ATR is also involved in the regulation of the b-subunit. ATR silencing using siRNA was associated with a significant lower content of HIF1b expression in whole extracts (Figure 1a ) as well as in the chromatin-loaded fraction (Figure 6c ). Similar decrease in HIF-b expression was observed in the WT/KD model (see Figures 1d and  6b ). This effect on HIF-1b expression is reproduced but to a lesser extent when pharmacological inhibitors are used (see also below, the results obtained with VE-821). In fact, in the presence of CGK733, the inhibition of HIF-1b expression was observed only at latter time points (from 2 h of hypoxia) and for higher doses of inhibitor (20 mM) compared with the conditions necessary to observe an inhibition of HIF-1a expression (from 1 h of hypoxia and 2.5 mM CGK733, respectively) (see Figure 2) . By opposition to HIF-1a, very few data have been reported regarding the regulation of HIF-1b expression that is generally regarded as a constitutively expressed protein. A recent study performed by the group of Rocha and co-workers 53 demonstrated that NF-kB controls HIF-1b transcriptional levels in response to cytokine stimulation in both human and mouse cells. However, as shown in Supplementary  Figure 2 , we did not observe any difference upon hypoxia in HIF-1b mRNA levels between ATR-deficient and -proficient cells. Rather, preliminary experiments performed in our laboratory favor a reduction in HIF-1b translation when ATR expression and/or activity were inhibited (Supplementary Figure 5) . While the molecular mechanism remains to be deciphered, these results highlight the pharmacological promises of the use of ATR inhibitors to counteract cancer cells hypoxic adaptation. To our knowledge this ability to decrease both HIF-1 subunits appears unique among the already identified HIF-1 inhibitors. 7 Therefore, our work opens new pharmacological opportunities to target hypoxic cells within the tumors. Due to replicative stress existing in tumor cells, disruption of ATR function through depletion or KD protein expression decreases cancer cell survival even in the absence of DNA-damaging agents. 54 This crucial role for ATR led to a growing interest in ATR as a target for anticancer drugs notably in tumors with high levels of replicative stress, 14 which is clearly the case in hypoxic areas. Interestingly, during the revision process of our manuscript, a new and highly selective inhibitor of ATR, VE-821, became commercially available. 54 As shown in Supplementary Figure 6 , this inhibitor, at doses that specifically inhibit ATR kinase activity in cellulo, 54 decreases the expression of both HIF-1 subunits as well as HIF-1 target genes, GLUT-1 and CAIX. We examined the dose-dependent effect of VE-821 on HIF-1 protein accumulation in two independent cellular models, HeLa and U2OS. VE-821 decreased hypoxic accumulation of HIF-1a protein in a dose-dependent manner with an IC 50 of 0. 3 and 3 mM for HeLa and U2OS cells, respectively. Again, as for CGK733-treated cells, the effect of VE-821 on HIF-1b expression was less pronounced with an IC 50 of 2.5 and 4.5 mM for HeLa and U2OS cells, respectively. At molecular levels, while VE-821 effect on HIF-1a expression was still observed in the presence of MG132, ruling out an effect on the protein degradation, a clear decrease of HIF-1a biosynthesis was observed (Supplementary Figure 6) . Similarly, exposure to VE-821 decreases HIF-1b biosynthesis (Supplementary Figure 6) . These results are very encouraging and confirmed the pharmacological promises of our work.
To conclude, we have demonstrated for the first time the role of ATR in activating an adaptive response to counterbalance oxygen deprivation through regulation of HIF-1 expression. Our work supports ATR inhibition as a new prospect for cancer therapy with the potential to decrease cellular adaptation in hypoxic tumors.
MATERIALS AND METHODS

Cell culture and treatments
Human cell lines U2OS (osteosarcoma) and HeLa (cervical adenocarcinoma) were grown in DMEM (Dulbecco's modified Eagle's medium; Invitrogen, Illkirch, France) supplemented with 10% fetal calf serum and antibiotics. U2OS stable clones allowing expression upon doxycycline addition of either WT ATR (WT, clone GW33) or dominant negative KD ATR (KD, clone GK41), kindly provided by Dr P Nghiem (University of Washington, Seattle, USA), were grown as previously described. 55 ATR WT or KD expression was induced with 2 mg/ml doxycycline for 48 h before experiments. All cells were grown in a humidified atmosphere at 37 1C with 5% CO 2 and experiments were done with non-confluent, exponentially growing cells at low passages. When indicated, normoxic and hypoxic cells were preincubated for 1 h in presence of CGK733 (20 mM, unless indicated), NU7026, LY294002, KU55933, MG132 (20 mM, respectively) or 5 mg/ml aphidicolin. All drugs are from Sigma-Aldrich (Saint-Quentin Fallavier, France), except KU55933 and aphidicolin, respectively, from Calbiochem (Darmstadt, Germany) and Alexis Biochemicals (Enzo Life Sciences, Villeurbanne, France). For hypoxia treatment, 60-70% confluent cells were cultured in a hypoxia chamber (InVIVO2 400, Ruskinn) flushed with 0.1% O 2 and 5% CO 2 with balance of 95% nitrogen at 37 1C. Control cells were placed in a 5% CO 2 and 95% air incubator (20% O 2 ) at 37 1C. At the end of the experiments, cells were washed twice with ice-cold phosphatebuffered saline, collected by scraping in normoxia or in the hypoxia chamber and placed in ice for centrifugation.
SiRNA-mediated knockdown
Transfections of U2OS with siRNAs were performed with lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instructions. Briefly, 1 Â 10 5 cells per sample were transfected in six-well plates with 5 ml of lipofectamine 2000 and siRNAs at a 30 and 40 nM final concentrations, respectively, for ATR and Chk1 in 1 ml of serum and antibiotics free medium. After 4 h, medium was replaced with complete medium. Total knockdown times were of 72 and 48 h, respectively, for ATR and Chk1. For ATR silencing, HP Validated siRNAs provided from Qiagen (Hilden, Germany) were used (siRNA 1: SI02660231, siRNA 2: SI02664347). siRNA directed against Chk1 was from Sigma-Aldrich (target sequence: 5 0 -UCGUGAGCGUUUGUUGAAC-3 0 ). Control siRNAs containing non-specific sequences was provided by Qiagen (SI1022076).
Cell extracts and western immunoblotting analysis
Whole-cell extracts and western blots were performed as previously described. 56 Membranes were incubated with primary antibodies (antibodies are listed in Supplementary Table 1) , washed and then incubated with the appropriate horseradish peroxidase-linked anti-mouse or anti-rabbit secondary antibody (Jackson Immunoresearch Laboratories, Suffolk, UK). To isolate nuclear soluble or chromatin subfractions from cells, a detergent-based extraction procedure was used as reported. 8 Briefly, cell fractionation was carried out by four consecutive extractions. The supernatant was collected at each step and labeled as fraction FI, FII, FIII, FIV. Pellets of about 2 Â 10 6 cells were first resuspended for 5 min on ice in 200 ml of extraction buffer (50 mM Hepes, pH 7.5, 150 mM NaCl, 1 mM EDTA) containing 0.2% NP40 supplemented with protease inhibitor (20 mg/ml phenylmethylsulfonyl fluoride, 1 mg/ml aprotinin, 1 mg/ml leupeptin, 1 mg/ ml pepstatin) and phosphatase inhibitors (50 mM NaF, cocktail inhibitor phosphatase I and II, all from Sigma). Following centrifugation at 1000 g for 5 min, the supernatants were collected (FI), the same extraction was realized and the supernatant were collected (FII) and pooled with the previous one. Therefore, the two-pooled first fractions were named FI. The pellets were further resuspended for 40 min on ice in 200 ml of extraction buffer containing 0.5% NP40 supplemented with protease inhibitor and phosphatase inhibitors. Pellets were clarified by centrifugation at 16 000 g for 15 min and the supernatants were collected (FIII). Insoluble FIV fractions were resuspended in a Tris pH 6.8 buffer supplemented with 2% SDS (sodium dodecyl sulfate), 10% glycerol and heated for 10 min at 100 1C. Equal aliquots of each fraction, derived from equivalent cell numbers, were separated by SDS-PAGE (SDS-polyacrylamide gel electrophoresis).
For measuring the expression levels of HIF-1a or HIF-1b in western blots experiments, the ImageJ software (NIH, Bethesda, MD, USA) was used. A loading control was used in each experiment for normalization (a-tubulin or b-actin for whole-cell extracts, HP1a for the chromatin-associated fraction FIV).
Determination of HIF-1a degradation
HIF-1a accumulation was induced with the hypoxia-mimetic agent DFX (260 mM) during 2 h. Cells were then treated with 100 mg/ml CHX in the presence or absence of CGK733 for the indicated time. Extracts were prepared at various time points (up to 1. 5 h) following the addition of CHX, as indicated in Results. HIF-1a steady-state levels were determined by western blot analysis. Similar experiments were performed using the ATRinducible cell lines, ATR WT and ATR KD.
Determination of protein biosynthesis
Cells were grown in methionine/cysteine-free DMEM for 2 h. Cells were placed in hypoxia chamber for 2 h and then labeled for 1 additional hour in hypoxia with methionine/cysteine-free medium containing 35 S-ATR regulates HIF-1 expression F Fallone et al methionine/cysteine (EasyTag; Perkin-Elmer, Maanstraat, Germany) at a final concentration of 100 mCi/ml. When inhibitors were used, cells were pre-treated for 1 h before hypoxia. Radiolabel incorporation was then monitored by immunoprecipitation of total cell lysates as previously described 46 using 5 mg of anti-HIF-1a (Novus Biochemicals, Cambridge, UK), anti-HIF-1b and anti-b-catenin antibodies (see Supplementary Table 1) . Immunoprecipitated proteins were separated by SDS-PAGE. Visualization and quantification were performed using Phosphorimager (Molecular Dynamics, Sunnyvale, CA, USA).
RNA extraction and quantitative PCR (qPCR)
Total RNA, reverse transcription and real time PCR were performed as previously described. 42 GLUT-1 oligonucleotides used were as follow: sense, 5 0 -GCGGAATTCAATGCTGATGAT-3 0 , antisense, 5 0 -CAGTTTCGAGAAG CCCATGAG-3 0 . For CAIX, we used Assays-on-Demand Gene Expression probes (Applied Biosystems, Courtaboeuf, France).
Plasmids and DNA constructions
All PCR were performed using Phusion polymerase (New England Biolabs, Beverly, MA, USA). DNA constructions were validated by DNA sequencing. A list of primers and restriction sites used for cloning is provided in Supplementary Table 2 . HIF-1a ORF-GFP expressing plasmid was generated by subcloning the BamHI-HIF-1a-NotI digestion fragment from pcDNA3-HA-HIF-1a (Addgene plasmid 18949) into a modified pEGFP-C1 (with a NotI site between BglII and BamHI). 5 0 UTR-ORF-3 0 UTR HIF-1a expressing plasmid was generated by combining by PCR HIF-1a cDNA from IMAGE clone 3842146, amplified using primers FL-5-F and FL-R, with the missing 5 0 UTR part obtained from U2OS genomic DNA, amplified using primers FL-F and FL-5-R. The resulting PCR products were fused by PCR using FL-F and FL-R primers and cloned into pEGFP-C1. 5 0 UTR-GFP plasmid was generated by combining by PCR the 5 0 UTR amplified from HIF-1a fulllength cDNA using primers 5-F and 5-R and GFP amplified from pEGFP-N1 using 5-GFP-R and 5-GFP-R primers. The resulting PCR products were fused by PCR using primers 5-F and 5-GFP-R and cloned into pEGFP-N1. GFP-3 0 UTR plasmid was generated by amplifying by PCR HIF-1a 3 0 UTR using 3-F and 3-R primers and cloned into pEGFP-C1. To generate a plasmid with HIF-1a ORF only, GFP was replaced in pEGFP-C1 by HIF-1a ORF amplified with ORF-F and ORF-R primers.
